Actinium Pharmaceuticals (ATNM) Price & Analysis

Compare

2,244 Followers

ATNM Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.03 - $2.41

Previous CloseN/A

Volume63.23K

Average Volume (3M)130.02K

Market Cap

$46.48M

Enterprise Value-$32.02M

Total Cash (Recent Filing)$59.93M

Total Debt (Recent Filing)$1.29M

Price to Earnings (P/E)―

Beta1.75

Next Earnings

Nov 24, 2025

EPS Estimate

-0.32

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.21

Shares Outstanding31,195,890

10 Day Avg. Volume142,167

30 Day Avg. Volume130,020

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.69

Enterprise Value/Revenue-39.54

Enterprise Value/Gross Profit155.46

Enterprise Value/Ebitda0.73

Forecast

1Y Price Target

$4.50

Price Target Upside179.50% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe clinical program for trials of Actimab-A in combination with Keytruda or Opdivo represents a significant event for the company, marking its first entry into solid tumors in the clinic.

Financial PerformanceActinium reported better-than-expected EPS for 2Q25, indicating strong financial performance.

Financial StabilityThe current cash runway now extends into 2028, indicating strong financial stability.

Regulatory ProgressActinium has reached an agreement with the FDA on the finalized protocol for the Phase 2/3 trial of Iomab-B, showing regulatory progress.

Bears Say

Resistance MechanismsCheckpoint inhibitors have transformed the treatment landscape for advanced cancers, yet efficacy can be limited due to resistance mechanisms, and Actimab-A targets CD33 to overcome these resistance mechanisms.

Treatment EfficacyIn vivo, ATNM-400 outperformed standard radiotherapies and enzalutamide, providing better tumor control as monotherapy and in combination.

Actinium Pharmaceuticals News

Actinium Pharmaceuticals to announces preclinical data from ATNM-400 program

Actinium Pharmaceuticals (ATNM) announced that the first-ever preclinical data from its ATNM-400 program in non-small cell lung cancer...

19h ago

ATNM

Actinium Pharmaceuticals’ New AML Treatment Study: A Potential Game Changer

Actinium Pharmaceuticals (($ATNM)) announced an update on their ongoing clinical study. Study Overview: Actinium Pharmaceuticals is conducting a...

1M ago

ATNM

Actinium Pharmaceuticals: Promising Advancements in Radiopharmaceutical Pipeline Drive Buy Rating

Maxim Group analyst Jason McCarthy has maintained their bullish stance on ATNM stock, giving a Buy rating yesterday....

2M ago

ATNM

Actinium Pharmaceuticals: Promising Pipeline and Strong Financials Drive Buy Rating

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Actinium Pharmaceuticals, retaining the price target of...

2M ago

ATNM

Actinium Pharmaceuticals’ ATNM-400 Shows Promise in Prostate Cancer Treatment, Earning Buy Rating

Actinium Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from...

2M ago

ATNM

Actinium Pharmaceuticals’ ATNM-400 shows improved survival in prostate cancer

Actinium Pharmaceuticals (ATNM) reported additional preclinical data supporting its ATNM-400 radiotherapy prostate cancer candidate at the 4th Annual...

2M ago

ATNM

Promising Preclinical Results for ATNM-400 Drive Buy Rating for Actinium Pharmaceuticals

Analyst Justin Walsh from JonesTrading reiterated a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report) and keeping...

4M ago

ATNM

Positive Outlook on Actinium Pharmaceuticals: Promising Preclinical Data and Strong Financial Position Drive Buy Rating

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Actinium Pharmaceuticals (ATNM...

4M ago

ATNM

Actinium highlights expanded data set for ATNM-400 in prostate cancer

Actinium Pharmaceuticals (ATNM) reported new preclinical data from its non-PSMA targeting radiotherapy prostate cancer candidate ATNM-400, that leverages...

4M ago

ATNM

ATNM Lawsuit Alert! Class Action Lawsuit Against Actinium Pharmaceuticals

A class action lawsuit was filed against Actinium Pharmaceuticals ($ATNM) by Levi & Korsinsky on March 27, 2025. The plaintiffs (shareholders)...

5M ago

ATNM

Promising Advancements and Strategic Collaborations Justify Buy Rating for Actinium Pharmaceuticals

Maxim Group analyst Jason McCarthy maintained a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report) on May...

5M ago

ATNM

Actinium Pharmaceuticals: Promising Pipeline and Strategic Partnerships Drive Buy Rating

Actinium Pharmaceuticals (ATNM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today....

5M ago

ATNM

Actinium Pharmaceuticals: Strong Buy Rating Driven by Promising Pipeline and Stable Financial Position

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report) today and...

5M ago

ATNM

Actinium enrolls first patient on the trial studying Iomab-ACT

Actinium Pharmaceuticals (ATNM) announced that the first patient was enrolled on the trial studying Iomab-ACT targeted conditioning with...

5M ago

ATNM

ATNM FAQ

What was Actinium Pharmaceuticals’s price range in the past 12 months?

Actinium Pharmaceuticals lowest stock price was $1.03 and its highest was $2.41 in the past 12 months.

What is Actinium Pharmaceuticals’s market cap?

Actinium Pharmaceuticals’s market cap is $46.48M.

When is Actinium Pharmaceuticals’s upcoming earnings report date?

Actinium Pharmaceuticals’s upcoming earnings report date is Nov 24, 2025 which is in 41 days.

How were Actinium Pharmaceuticals’s earnings last quarter?

Actinium Pharmaceuticals released its earnings results on Mar 14, 2025. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.374 by $0.164.

Is Actinium Pharmaceuticals overvalued?

According to Wall Street analysts Actinium Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Actinium Pharmaceuticals pay dividends?

Actinium Pharmaceuticals does not currently pay dividends.

What is Actinium Pharmaceuticals’s EPS estimate?

Actinium Pharmaceuticals’s EPS estimate is -0.32.

How many shares outstanding does Actinium Pharmaceuticals have?

Actinium Pharmaceuticals has 31,195,890 shares outstanding.

What happened to Actinium Pharmaceuticals’s price movement after its last earnings report?

Actinium Pharmaceuticals reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.374. Following the earnings report the stock price went up 2.5%.

Which hedge fund is a major shareholder of Actinium Pharmaceuticals?

Currently, no hedge funds are holding shares in ATNM

Actinium Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-130.59%

Trailing 12-Months

Asset Growth

-29.87%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Actinium Pharmaceuticals

Actinium Pharmaceuticals (ATNM) is a biopharmaceutical company specializing in the development of targeted therapies for patients with unmet needs in oncology. The company primarily focuses on developing radioimmunotherapy and other innovative treatments that leverage its expertise in radioisotopes and antibody technology. Actinium's core products are centered around its proprietary Antibody Radiation-Conjugate (ARC) platform, which aims to deliver potent radiation directly to cancer cells while sparing healthy tissue.

Actinium Pharmaceuticals (ATNM) Earnings & Revenues

Historic Earnings Reports

ATNM Stock 12 Month Forecast

Average Price Target

$4.50

▲(179.50% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","9":"$9","2.25":"$2.25","4.5":"$4.5","6.75":"$6.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.25,4.5,6.75,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.61,1.870769230769231,2.1315384615384616,2.3923076923076922,2.653076923076923,2.913846153846154,3.1746153846153846,3.4353846153846153,3.6961538461538463,3.9569230769230765,4.217692307692308,4.478461538461539,4.739230769230769,{"y":5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.61,1.8323076923076924,2.0546153846153845,2.276923076923077,2.499230769230769,2.7215384615384615,2.943846153846154,3.166153846153846,3.3884615384615384,3.6107692307692307,3.8330769230769226,4.055384615384615,4.277692307692307,{"y":4.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.61,1.7938461538461539,1.9776923076923079,2.161538461538462,2.3453846153846154,2.529230769230769,2.7130769230769234,2.896923076923077,3.0807692307692305,3.2646153846153845,3.4484615384615385,3.632307692307692,3.8161538461538465,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.78,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.15,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.2,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.62,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.71,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.26,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.49,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.49,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.35,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.61,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >